Cemdeicy S.C.P.

Mérida, Yucatán 97130

0 studies enrolling now · 3 studies all time

What they study most

Atopic Dermatitis, Systemic Lupus Erythematosus

Studies at this site

• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) — Stopped early
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus — Stopped early